Investigating the Role of Mitochondrial DNA in Alzheimer’s Disease Biomarker Expression

Background Impaired metabolic function and mitochondrial metabolism increase risk of Alzheimer’s Disease (AD) development, which is the leading form of dementia and one of the main causes of death in older adults. Altered mitochondrial function can reduce efficiency of cellular maintenance processes like mitophagy and proteostasis, leading to protein aggregation and cytotoxicity. Mitochondria differ from other organelles, as they have their own unique genetic component (mtDNA), which encodes proteins essential for mitochondrial translation and oxidative metabolism. Differences in mtDNA between individuals affect mitochondrial function and can increase risk of certain diseases; it is not well studied how mtDNA impacts AD pathology. Method SH‐SY5Y cytoplasmic hybrid (cybrid) cell lines were generated using mtDNA from clinical research volunteers (n = 18 cognitively healthy (CH) older adults (mean age 73.8), n = 7 MCI (mean age 78.1), n = 10 AD (mean age 75.3)) enrolled in the Relationship of Energetics and Cognitive Trajectory study. Groups did not differ by sex. Cells were analyzed for protein expression by western blot, metabolic flux by Agilent Seahorse XF Analyzer, and protein secretion by ELISA. Plasma pTau217 (AlzPATH) and Aβ42 (N4PE) were assessed by Simoa HD‐X (Quanterix) to compare blood biomarker values with cellular outcomes. Result Cybrids from individuals with MCI and AD had elevated intracellular pTau217 (p = 0.033, p = 0.006 respectively). Cybrids from CH individuals secreted significantly more Aβ42 than those from individuals with AD (p = 0.002). Cybrid pTau217 and plasma pTau217 from the same subjects correlated significantly (p